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Cathelicidins are a class of small cationic peptide anti-
biotics that are expressed in skin and in other epithelial
cells and are an active component of mammalian in-
nate immunity. Human cathelicidin (hCAP18/LL-37)
consists of a conserved prosequence called the cathelin-
like domain and a C-terminal peptide named LL-37. To
date, our understanding of the cathelin-like domain was
very limited. To bring insight into the function of this
evolutionarily conserved prosequence, we produced re-
combinant human cathelin-like protein and full-length
hCAP18/LL-37 in Escherichia coli. As the cathelin-like
protein shares homology with the cystatin family of cy-
steine protease inhibitors, we ¢rst analyzed the e¡ect of
the cathelin-like recombinant protein on the cysteine
protease cathepsin L. We found that the cathelin-like
protein inhibited protease activity. Next, we tested the
cathelin-like protein for antimicrobial activity using
solid phase radial di¡usion and liquid phase killing
assays. The cathelin-like prosequence, but not full-length
hCAP18/LL-37, killed human pathogens including
E. coli and methicillin-resistant Staphylococcus aureus at
concentrations ranging from 16 to 32 lM. Together
these ¢ndings suggest that after proteolytic cleavage
the cathelin-like domain can contribute to innate host
defense through inhibition of bacterial growth and lim-
itation of cysteine-proteinase-mediated tissue damage.
As these dual functions are complementary to the LL-
37 peptide released from the C-terminus of full-length
hCAP18/LL-37, human cathelicidin represents an
elegant multifunctional e¡ector molecule for innate im-
mune defense of the skin. Key words: Innate immunity/
protease/infection/skin/staphylococcus. J Invest Dermatol
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mall, cationic antimicrobial peptides (AMPs) are nat-
urally occurring antibiotics of the innate immune sys-
tem. AMPs are widely distributed in animals and plants
and are among the most ancient host defense factors
(Ho¡mann et al, 1999). Their spectrum of activity in-
cludes Gram-positive and Gram-negative bacteria as well as fungi
and certain viruses (Boman, 2000; Zaslo¡, 2002). As resistance of
pathogenic microbes to conventional antibiotics increases, re-
searchers are exploring these endogenous antibiotics as a potential
source for new therapies against a variety of infectious diseases. In
humans, there are several classes of known AMPs including a-
defensins, b-defensins, and cathelicidins. Cathelicidins are found
in several mammalian species and accumulating evidence sup-
ports a key role for this class of AMPs in innate immune defense
(for review see Gennaro and Zanetti, 2000; Ramanathan et al,
2002; Zaiou and Gallo, 2002). Recently, development and char-
acterization of a cathelicidin knockout mouse provided evidence
that endogenous expression of an AMP protects the host against
invasive bacterial infection of the skin (Nizet et al, 2001). Addi-
tional investigations have identi¢ed roles for cathelicidins in
speci¢c clinical disease states. Production of cathelicidins is
induced in response to epithelial wounding or infectious
challenge (Dorschner et al, 2001; Schaller-Bals et al, 2002), or
suppressed by the virulence mechanisms of certain bacterial
pathogens, e.g., Shigella dysenteriae (Islam et al, 2001). Cathelicidin
expression is also di¡erentially a¡ected in certain chronic in£am-
matory disorders. In psoriasis, cathelicidin levels are elevated and
secondary infection is rare (Frohm et al, 1997), whereas in atopic
dermatitis cathelicidin expression is de¢cient and bacterial or viral
superinfection is common (Ong et al, 2002). Therapeutic bene¢ts
of cathelicidin have been demonstrated experimentally, including
decreased bacterial colonization of skin wounds following topical
administration (Cole et al, 2001) and improved pulmonary bacter-
ial clearance with cathelicidin overexpression through viral gene
transfer (Bals et al, 1999a,b).
Cathelicidin proteins are composed of two distinct domains:
an N-terminal ‘‘cathelin-like’’ or ‘‘prosequence’’ domain and the
C-terminal domain of the mature AMP. The highly variable
C-terminal domains of cathelicidins were among the earliest
mammalian AMPs to show potent, rapid, and broad-spectrum
killing activity (Zanetti et al, 1990; Gennaro et al, 1998). In con-
trast, the function of the conserved prosequence domain of cathe-
licidins is less well understood. The term ‘‘cathelin-like’’ derives
from the similarity of this sequence with that of cathelin, a
12 kDa protein isolated from porcine neutrophils that shares
similarity with the cystatin superfamily of cysteine protease in-
hibitors (Ritonja et al, 1989; Storici et al, 1996; Scocchi et al, 1997).
Cathelicidins are expressed in neutrophils and myeloid bone
marrow cells (Zanetti et al, 1990; Gallo et al, 1997; Ganz and
Lehrer, 1997; Sorensen et al, 1997) and at most epithelial surfaces
(Frohm et al, 1997; Harder et al, 1997; Bals et al, 1998; Dorschner
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et al, 2001), and were the ¢rst AMPs discovered in mammalian
skin due to their presence in wound £uid (Gallo et al, 1994). In
the neutrophil, cathelicidins are synthesized as a full-length
precursor and targeted to the secondary granules where they are
stored. Upon stimulation, the full-length cathelicidin protein is
proteolytically processed to unleash the microbicidal activity of
the C-terminal peptide from the cathelin-like domain (Zanetti
et al, 1991; Sorensen et al, 2001).
Although the killing activities and biologic functions of ma-
ture cathelicidin antimicrobial peptides have been investigated ex-
tensively, a satisfactory description and evidence of the function
of the conserved cathelin-like prosequence are still unavailable.
The structure of this 96^104 residue protein domain is believed
to be stabilized by four cysteines engaged in two disul¢de bonds
(Storici et al, 1996; Sanchez et al, 2002a,b). These four cysteines as
well as their relative positions are well conserved in all species.
The strict evolutionary conservation of this domain and its
similarity to cystatins, a family of proteinase inhibitors, suggests
it plays a speci¢c and independent biologic function in host
defense (Gennaro and Zanetti, 2000).
To investigate possible function(s) of the cathelin-like domain,
we selected the sole human cathelicidin, hCAP18/LL-37 (cationic
antibacterial protein of 18 kDa). The C-terminal mature AMP of
37 amino acids (LL-37) of CAP18/LL-37 has been well character-
ized (Agerberth et al, 1995). Here we report prokaryotic expression
of recombinant full-length hCAP18/LL-37 and its cathelin-like
prosequence.We show that the human cathelin-like domain acts
as a cysteine proteinase inhibitor and discover that it exhibits
antibacterial activity against pathogens including Escherichia coli
and methicillin-resistant Staphylococcus aureus (MRSA). This anti-
microbial activity is distinct from that of the LL-37 peptide.
These ¢ndings suggest that the cathelin-like domain of hCAP18/
LL-37 is a distinct contributor to skin innate host defense
through inhibition of both bacterial growth and cysteine-
proteinase-mediated tissue damage.
MATERIALS AND METHODS
Construction of human cathelicidin expression vectors Expression
plasmids containing the human full-length cathelicidin cDNA (hCAP18/
LL-37) residues (31^170) or the cathelin-like domain residues (31^131)
were constructed as fusion proteins in the pET-28a vector (Novagen,
Madison, WI) using standard methods (Sambrook et al, 1989). High-
¢delity polymerase chain reaction was used to amplify the coding
sequence of hCAP18/LL-37 with primers designed from the published
sequence (Gudmundsson et al, 1996): forward primer P1, 50 -TCC-
GAGCTCGACGATGACGATAAGCTGCTGGGTGATTTCTTCCGG-30,
containing a SacI recognition site and enterokinase cleavage site
(underlined), and reverse primer P2, 50 -CCGCTCGAGCTAGGACTCT-
GTCCTGGGTACAAGATTCCG-30. For plasmid pET-Cath, we used
primer P1 (above) and reverse primer P3, 50 -CCGCTCGAGCTACTAGG-
CAAATCTCTTGTTATCCTT-30. P2 and P3 both contain stop codons
and XhoI restriction site extensions. SacI and XhoI digested polymerase
chain reaction amplicons were used for unidirectional ligation into pET-
28 vector. The pET-hCAP18 and pET-Cath constructs were con¢rmed by
plasmid puri¢cation and direct DNA sequencing.
Expression of cathelicidin proteins pET-hCAP18 or pET-Cath were
transformed into protease-de¢cient E. coli strain BL21 (DE3). Overnight
cultures of each in Luria^Bertani broth (LB) (1% bactotryptone, 0.5%
yeast extract, 1% NaCl) supplemented with kanamycin (50 mg per ml)
were used to inoculate 1 l LB broth and then grown at 371C with
agitation to 0.6 OD at 600 nm. Expression was induced by addition of
isopropyl-b-D-thiogalactopyranoside (IPTG) to a concentration of 0.5
mM. Cells were harvested by centrifugation (6500 g) for 10 min at 41C
and then resuspended in 50 ml ice-cold sonication bu¡er (0.1 M Tris^HCl
pH 8.0; 0.01 M Na2HPO4, 0.1 M NaCl; 0.05 M ethylenediamine tetraacetic
acid (EDTA); 0.005 M b-mercaptoethanol) supplemented with the protease
inhibitors 0.1% aprotinin and 2 mM phenylmethylsulfonyl £uoride. Cells
were disrupted by sonication on ice and the mixture was centrifuged at
20,000 g for 30 min to separate the insoluble material. Recombinant
protein solubility was assessed by comparative sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) separation of both the
supernatant and the pellet fractions. The supernatant fraction containing
soluble recombinant proteins was collected and guanidine^HCl and b-
mercaptoethanol were added to ¢nal concentrations of 6 M and 0.1%,
respectively. The pellet resulting from the centrifugation was washed with
50 mM Tris^HCl and 5 mM EDTA. Insoluble full-length hCAP18/LL-37
and cathelin-like proteins were extracted overnight at 41C with lysis bu¡er
supplemented with 6 M guanidine^HCl and b-mercaptoethanol with a
yield of 70%^90% without degradation. The suspension was then
centrifuged at 20,000 g for 30 min to remove the remaining insoluble
material. The supernatants of both extractions were dialyzed against 200
mM NaCl, 200 mM L-arginine, 10 mM b-mercaptoethanol, and 50 mM
Tris^HCl pH 8.0, followed by extensive dialysis against 10 mM Tris^HCl
pH 7.5.The solution was centrifuged for 10 min at 15,000 g to remove any
precipitate. Proteins were pooled with the soluble fractions obtained
earlier.
Puri¢cation of recombinant proteins Immobilized metal a⁄nity
chromatography was employed. The supernatant was dialyzed against
bu¡er A consisting of 0.5 M NaCl, 0.02 M Na2HPO4 pH 7.5. Proteins
were loaded onto an Ni2þ^NTA 5 ml His-Trap column (Pharmacia
Biotech, Piscataway, NJ) previously equilibrated with bu¡er A to which
40 mM imidazole was added (£ow rate 1 ml per min). The column was
washed with 50 volumes of bu¡er A containing 40 mM imidazole to
remove unspeci¢c bound materials and bound proteins were eluted with
500 mM imidazole in bu¡er A, collecting 1 ml fractions. The elution
pro¢le was monitored by separation of samples by SDS-PAGE. Fractions
containing proteins of interest were pooled and dialyzed against 0.5 M
NaCl, 0.02 M Na2HPO4 pH 7.5 and the puri¢cation step was repeated at
least twice. Eluted fractions were pooled and were dialyzed against
enterokinase bu¡er (50 mM Tris^HCl pH 8.0, 1mM CaCl2, 0.1% Tween-20).
Enterokinase digestion The upstream 43-residue N-terminal fusion
sequence of pET containing the enterokinase recognition sequence
DDDDK was cleaved from the recombinant hCAP18/LL-37 and Cath
proteins by digestion with enterokinase (obtained as a 1 unit per ml
solution from Invitrogen, Carlsbad, CA). The reaction was incubated at
371C overnight with an enzyme:protein substrate ratio of 1:25. Digested
proteins were dialyzed against 10 mM Tris^HCl pH 7.5 and then proteins
were applied onto a Superdex-75 column (2.6100 cm) and eluted using
10 mM phosphate bu¡er (pH 7.5) containing 150 mM NaCl at room
temperature. Fractions containing proteins of interest were collected and
dialyzed against 10 mM Tris^HCl pH 7.5.
SDS-PAGE and immunoblotting The purity of cathelin-like or
hCAP18/LL-37 protein was ¢rst con¢rmed by SDS-PAGE followed by
Coomassie blue and silver staining. For Western blot, protein was
separated by SDS-PAGE and was then transferred to nitrocellulose
membranes using the Bio-Rad system. Membranes were blocked for 1 h
at room temperature with 0.1% low fat milk in 50 mM Tris^HCl, pH 7.5,
150 mM NaCl, 0.2% Tween-20, and were probed overnight at 41C
with chicken polyclonal anticathelin-like antibodies (1:15,000) to detect
cathelin-like protein or with rabbit anti-LL-37 antibodies (1:6000) to
detect full-length hCAP18/LL-37, followed by extensive washing.
Immunoreactive materials were detected by enhanced chemiluminescence
using horseradish peroxidase conjugated antichicken antibodies (1:20,000)
or horseradish peroxidase conjugated antirabbit antibodies (1:5000).
Matrix-assisted laser desorption/ionization time of £ight (MALDI-
TOF) mass spectrometry A MALDI-TOF mass spectrometer (Applied
Biosystems, Framingham, MA) was used to analyze puri¢ed proteins and
further con¢rm identity and purity. Protein samples were prepared
for analysis by mixing in a 1:1 ratio with sinapinic acid matrix (3,5-
dimethoxy-4-hydroxycinnamic acid). Calibration was performed using
internal standards: bovine insulin, apomyoglobin, and thioredoxin (Core
facility at the University of California, San Diego).
Proteinase activity inhibition assay Proteinase inhibitory activity
of recombinant cathelin-like protein was assayed spectro£uorometrically
by measuring its inhibitory action against human liver cathepsin L
(Calbiochem, CA). For the reaction assay, cathepsin L (0.1 mU) in the
assay bu¡er (340 nM sodium acetate, 60 mM acetic acid, 8 mM
dithiothreitol, and 4 mM EDTA, pH 5.5, supplemented with 0.1% BRIJ
35) was preincubated for 2 min at 301C with 106 M cathelin-like protein
before adding 20 mM of substrate Z-Phe-Arg-7-amido-4 -methylcoumarin
(Calbiochem). When hydrolyzed by cathepsin L, this substrate releases
highly £uorescent 7-amido-4-methylcoumarin (AMC). AMC intensity
was determined using a spectrophotometer at 370 nm excitation and an
emission wavelength of 460 nm. One unit was de¢ned as the amount of
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enzyme that will hydrolyze 1.0 mmol of Z-Phe-Arg-AMC per min at 251C,
pH 5.5.
Antimicrobial assays E. coli (ATCC 25922), Pseudomonas aeruginosa
(ATCC 8427), Salmonella typhimurium (ATCC 13311), Proteus vulgaris (ATCC
8427), Staphylococcus epidermidis (ATCC 12228), and MRSA (ATCC 33591)
isolates were maintained on trypticase soy broth (TSB) agar plates.
Individual colonies were selected and cultured overnight in TSB,
subcultured once at 1:50 in fresh TSB, and then grown to stationary phase
for use in all experiments. The radial di¡usion assay was performed as
described previously (Steinberg and Lehrer, 1997) in 0.5% agarose and
0.75% tryptone brought to ebullition and cooled to 431C, and then
mixed with 100 ml of bacterial suspension and poured into a 10 cm Petri
dish. A series of small wells (diameter, 3 mm) were punched in the plate
after the agarose solidi¢ed. Two microliters of test samples were applied in
each well. Plates were incubated at 371C overnight to allow visible growth
of bacteria. Antibacterial activity was indicated by the clear zone (no
bacterial growth) around the well.
The colony-forming assay (CFU) was performed as described previously
(Valore et al, 1996). Brie£y, bacterial cultures (E. coli or MRSA) were
collected at the logarithmic phase of growth in TSB, washed twice with
phosphate-bu¡ered saline, pH 7.4, and diluted to 104 CFU per ml in 10
mM phosphate bu¡er, pH 7.4, Na2HPO4/NaH2PO4^1% TSB (g per l).
Forty-¢ve microliters of bacterial suspension were mixed with 5 ml of
H2O (control) or with 5 ml of di¡erent concentrations of cathelin-like
proteins, and the mixture was incubated at 371C. Every 30 min, a 10 ml
aliquot of the reaction mixture was plated directly onto a TSB agar plate
and then incubated at 371C overnight for enumeration of CFU. Data are
reported as growth index¼¢nal CFU/CFU in initial inoculum.
Processing of full-length hCAP18/LL-37 to cathelin-like protein
and LL-37 Full-length hCAP18/LL-37 recombinant protein (10 ng) was
incubated with 10 mU of human neutrophil elastase (Calbiochem) at 371C
for 30 min. The sample was subsequently boiled in Laemmli sample bu¡er
and run by SDS-PAGE followed by immmunoblot analysis with
anticathelin-like and anti-LL37 antibodies.
RESULTS
Expression and puri¢cation of cathelicidin proteins in E. coli
In this study, cathelin-like protein and full-length cathelicidin
hCAP18/LL-37 proteins were required for functional analysis. In
order to achieve e⁄cient expression of these proteins in E. coli,
cDNA encoding full-length hCAP18/LL-37 or cathelin-like
domain alone were cloned into the pET 28a(þ ) expression
vector system (Fig 1a). This system generates fusion proteins
with an N-terminal peptide of 5 kDa containing a His(6)
puri¢cation tag. Through primer design, a sequence
corresponding to an enterokinase cleavage site, pentapeptide
(Asp)4 -Lys, was inserted after the fusion domain and before the
cDNA of interest. Cultures of BL21 (DE3) bacteria transformed
with either pET-hCAP18 or pET-Cath were then used
for expression following IPTG induction. Over 70% of
recombinant cathelin-like proteins were found in the soluble
fraction. Only about 40% of full-length cathelicidin proteins
were soluble, however. The remaining protein was found in the
insoluble fraction. The expression of cathelicidin proteins with
His-tag sequence at their N-terminus allowed for convenient
puri¢cation from other soluble bacterial proteins using
immobilized metal a⁄nity chromatography. Proteins were
further puri¢ed to homogeneity using size exclusion
chromatography. The purity of recombinant cathelin-like
protein after elution was ¢rst checked by SDS-PAGE (Fig 1b). A
band of approximately 16 kDa, which corresponds to the
cathelin-like region and the fusion sequence (5 kDa), was
detected by Coomassie blue staining (Fig 1b). The identity of
the bands of expected size was con¢rmed byWestern blot using
antibodies against the cathelin-like domain (Fig 1c). A single
band of approximately 32 kDa was also detected that probably
corresponds to a homodimer of cathelin-like protein. These
results demonstrated the e¡ectiveness of the expression system
used and recovery after puri¢cation (10^15 mg per l). Full-length
hCAP18/LL-37 was identically puri¢ed and con¢rmed by
identical techniques (data not shown). Cathelicidin proteins were
removed from the N-terminal tag by cleavage with enterokinase.
Optimization studies found that enterokinase treatment yielded
complete cleavage when digestion was carried out at 371C
overnight. No nonspeci¢c cleavage or degradation was observed
during this period as con¢rmed by Coomassie blue staining of
the gel (Fig 1c, lane 2). Following enterokinase cleavage,
cathelicidin proteins were further puri¢ed by size exclusion
chromatography, fractions were analyzed by SDS-PAGE, and
then identity and purity were con¢rmed by mass spectrometry
(Fig 1d). Approximately 50% of the preparations of
recombinant cathelin-like protein displayed the expected peak at
11167.5 mass units by matrix-assisted laser desorption/ionization
in agreement with theoretical mass and full disul¢de bond
formation of this protein. To further con¢rm the identity of
hCAP18/LL-37, the recombinant protein was treated with
elastase to observe if this protein was processed similarly to the
native cathelicidin. Elastase treatment generated a band
migrating at the same size as synthetic LL-37, and a band at 14
kDa as seen by Western blot using anti-LL-37 antibodies (data
not shown). This pro¢le is similar to that observed with the
previously reported experiments on native human cathelicidins
isolated from neutrophils and treated with elastase or proteinase 3
(Sorensen et al, 2001). These experiments do not provide evidence
of correct assembly of the disul¢de bridges of recombinant
hCAP18, however.
Proteinase inhibitory activity To evaluate the possible
protease inhibitory activity action of cathelin-like protein, the
activity of human cathepsin L was measured in the presence or
absence of recombinant cathelin-like protein using the
£uorescent substrate Z-Phe-Arg-AMC. As shown in Fig 2,
Figure1. Expression and characterization of recombinant cathelici-
din proteins. (a) Schematic representation of cathelicidin expression sys-
tem in E. coli. (b) SDS-PAGE of cathelin-like protein by Coomassie blue
staining; MW, molecular weight markers (from top to bottom: 45K; 30K;
20.1K; 14.3K; 6.5K; 3.5K; 2.5K); lanes 1 and 2 are cathelin-like protein before
and after digestion with enterokinase. (c) Western blot analysis using anti-
cathelin-like antibodies; lanes 1 and 2, cathelin-like protein before and after
digestion with enterokinase. (d) MALDI-TOF mass spectrometry. Mo-
lecular mass of pure human cathelin-like protein is a single peak at 11167.5
Da. Internal standards were included and are seen as accompanying peaks.
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there was a linear relationship (R2¼ 0.98^99) between
the control (cathepsin L alone) and the test (cathepsin Lþ
cathelin-like protein). The generation of £uorescence was
signi¢cantly decreased (slope¼1.31 vs 0.71, respectively) when
cathelin-like protein was added to the reaction. The hydrolytic
activity of the cysteine proteinase cathepsin L was inhibited
by 46% when cathelin-like protein was added at a ¢nal con-
centration of 106 M. Parallel experiments with recombinant
full-length hCAP18/LL-37 did not demonstrate inhibitory
activity (data not shown).
Antimicrobial activity of recombinant cathelin-like protein
Recombinant cathelicidins were tested for antimicrobial activity
using a standard radial di¡usion assay. Di¡erent concentrations of
the cathelin-like protein were loaded into wells on assay plates
containing Gram-positive MRSA, S. epidermidis, and strains of
the Gram-negative bacterial species E. coli, S. enteritidis, P. vulgaris,
and P. aeruginosa. Cathelin-like protein had minimal inhibitory
activity against growth of MRSA at 32 mM and E. coli at 16 mM,
but did not inhibit growth of P. aeruginosa (Fig 3a). Similarly,
cathelin-like protein inhibited growth of S. epidermidis (32 mM)
but not S. enteritidis or P. vulgaris. The full-length recombinant
cathelicidin hCAP18/LL-37 did not demonstrate inhibitory
activity against any of the bacteria tested, even at concentrations
greater than 64 mM. In contrast to cathelin-like protein, the C-
terminal peptide domains of the human and mouse cathelicidins
(LL-37 and CRAMP, respectively) were inactive against the
Gram-positive bacteria tested in this assay system, but were
highly active against E. coli, P. aeruginosa, and S. enteritidis as
previously described (Agerberth et al, 1995; Gallo et al, 1997;
Turner et al, 1998; Bals et al, 1999).
Next we investigated cathelin-like protein in a standard liquid
phase AMP testing assay to validate the observed activities on
agar (Fig 3b, c). As LL-37 was active against E. coli but inactive
against MRSA in the radial di¡usion assay, whereas cathelin-like
protein was active against both, we chose these two bacteria for
comparison of antimicrobial activity of full-length cathelicidin
and its two distinct domains. With E. coli, addition of cathelin-
like protein (16 mM) resulted in marked growth inhibition
compared to the untreated controls, whereas LL-37 at 3 mM was
bactericidal (Fig 3c).With MRSA, an inverse pattern of activity
was seen with cathelin-like protein and LL-37. Cathelin-like
protein decreased MRSA CFU for the ¢rst 15 min and then was
bacteriostatic, whereas LL-37 had no e¡ect even at 32 mM. Full-
length hCAP18/LL-37 (32 mM) did not show any activity against
E. coli or MRSA (Fig 3b, c). These results are consistent with
those obtained in the radial di¡usion plate assay. Taken together,
our results demonstrate that cathelin-like protein possesses
Figure 2. Proteinase inhibitory activity of recombinant cathelin-
like protein. Hydrolysis of the £uorogenic substrate Z-Phe-Arg-AMC
by cathepsin L (protease alone), and in the presence of cathelin-like protein
(protease þ cathelin). Fluorescence measurements were made as described
in Materials and Methods. Data demonstrate inhibition of cathepsin L by the
addition of cathelin-like recombinant protein. Slopes, intercepts, and cor-
relation coe⁄cients were calculated by linear regression. Data were re-
corded 10 times over 30 min and are representative of two experiments.
Figure 3. Growth inhibition of MRSA, E. coli, and P. aeruginosa by
cathelin-like protein. (a) Inhibition zone assay on tryptone/agarose plates
with MRSA. Clear circles show lack of bacterial growth. Lanes 1, 3, 5, bot-
tom row: cathelin-like protein at 64 mM, 32 mM, 16 mM, respectively. Lane 2,
top row: 32 mM of His-tagged cathelin-like protein before cleavage. Lane 4,
top: enterokinase enzyme alone. All assays were performed in duplicate and
repeated three times. (b), (c) CFU assay: growth inhibition of (b) MRSA
and (c) E. coli, cultured in 10 mM phosphate and 1% TSB (pH 7.4) and then
supplemented with di¡erent concentrations of human cathelin-like protein.
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inherent antimicrobial activity and suggest a novel role for this
protein in host defense.
DISCUSSION
The expression of the cathelicidin gene product is an important
determinant of resistance to infection in mammals (Nizet et al,
2001). Heretofore, the antimicrobial activity of this molecule has
been attributed to the action of the C-terminal peptide (in hu-
mans known as LL-37) after proteolytic processing of the precur-
sor protein (in humans known as hCAP18/LL-37) to ‘‘remove’’ the
N-terminal cathelin-like domain. The major goal of this study
was to explore potential biologic function(s) of the evolutionarily
highly conserved cathelin-like domain of human cathelicidin.We
produced recombinant human cathelin-like protein and unpro-
cessed full-length cathelicidin proteins in bacteria. These proteins
were puri¢ed and characterized immunologically and physico-
chemically. Due to the complex structure of the cathelin-like do-
main, it was di⁄cult to obtain protein that was soluble. When
soluble, however, functional analysis demonstrated that the re-
combinant cathelin-like domain possessed both antimicrobial
and cysteine proteinase inhibitory activities. The cathelin-like
protein caused inhibition of growth of some Gram-negative (E.
coli) and Gram-positive (S. aureus) bacterial species. This activity
was distinct from the known antimicrobial spectrum of the ma-
ture C-terminal peptide. Human cathelin-like protein also inhib-
ited the action of the lysosomal cysteine proteinase cathepsin L.
The recombinant full-length hCAP18/LL-37 cathelicidin lacked
both activities before processing. Our ¢ndings suggest that
the human cathelicidin gene encodes an inactive precursor
(full-length hCAP18/LL-37) that, once processed by enzymes
such as elastase or proteinase-3, generates two distinct antimicro-
bial molecules: cathelin-like protein and the mature LL-37 AMP.
These data are distinct from an earlier study showing that native
bovine proBac 5 isolated from bovine neutrophils can inhibit the
activity of cathepsin L (Verbanac et al, 1993). Bovine pro-Bac5 clo-
sely resembles the full-length hCAP18/LL-37 that was inactive in
our experiments. Our data suggest that recombinant human ca-
thelin-like protein alone is an inhibitor of cysteine proteinase ca-
thepsin L. Lack of activity of the full-length protein may re£ect
incorrect folding of our recombinant protein. Alternatively, the
puri¢ed native pro-Bac5 previously reported may have contained
undetectable amounts of cleaved cathelin-like protein that
imparted activity.
Studies have reported that the lysosomal cysteine proteinase ca-
thepsin L is present in in£ammatory cells, and may contribute
substantially to tissue injury at in£ammatory lesions due to its
potent elastinolytic and collagenolytic activities (Mason et al,
1986). As cathelin-like protein is similar to cystatins, which are
known to have diverse functions including the ability to inhibit
cysteine proteinases, we tested recombinant cathelin-like protein
for proteinase inhibitory action. Indeed, recombinant human ca-
thelin-like protein was able to inhibit the proteolytic activity of
the human cysteine proteinase cathepsin L. This phenomenon
could be an evolutionary system designed to mitigate tissue in-
jury and other potentially deleterious e¡ects of cathepsin L, and
potentially other proteinases, released from lysosomes during in-
£ammatory responses. Moreover, several human pathogens se-
crete cysteine proteases that have been shown to play a role in
disease pathogenesis, including SpeB and IdeS of Streptococcus pyo-
genes (Lukomski et al, 1999; von Pawel-Rammingen et al, 2002),
Lys-gingipain of Porphyromonas gingivalis (Kuboniwa et al, 2001),
and the extracellular cysteine proteases Ehcp1^6 of Entamoeba
histolytica (Zhang et al, 2000). Theoretically, the inhibition of such
microbial virulence determinants may be another adaptive func-
tion of the cathelin-like domain in innate immune defense.
Studies are under way to express su⁄cient quantities of recom-
binant cathelin-like protein in eukaryotic expression systems
to determine the a⁄nity and inhibitory constant (Ki) with
cathepsin L and a range of other cysteine proteases.
Mammalian cathelicidin is produced as an inactive precursor
that is proteolytically cleaved inside activated neutrophils and at
epithelial sites of in£ammation. Following this activation step,
the active AMP and the cathelin-like domain with antimicrobial
and cysteine protease inhibitor activities become available. Re-
cent research has shown that granule proteases such as elastase
and cathepsin each play important roles in neutrophil function
and resistance to infection (Reeves et al, 2002). It is possible that
protease cleavage of full-length cathelicidin into two active anti-
microbial agents is a critical step in the pathway to microbial kill-
ing (Cole et al, 2001). The prosequence inhibition of cathepsin
activity may represent a feedback loop to control the magnitude
of local tissue degradation during the in£ammatory process. It re-
mains to be determined whether cathelicidin prosequence inhibi-
tion of proteases in itself represents an antimicrobial property.
Motifs involved in the interaction of cystatins with cysteine pro-
teinases are not fully conserved in the cathelin-like domain, how-
ever. For example, glycine 9 (chicken cystatin numbering), a
conserved residue found in all known sequences of inhibitory cy-
statins (Abrahamson et al, 1987; Ritonja et al, 1989), is not present
in cathelin-like protein. Another highly conserved sequence,
QXVXG (residues 53^57), is also not present (Ritonja et al,
1989), indicating that the interaction with cysteine proteinases is
di¡erent. Overall, the proteinase inhibition activity of cathelin-
like protein may be an alternative strategy of the host to control
the regulation of its own enzymes and also to defend itself against
microbe proteinases.
Next, we investigated the antimicrobial activity of the recom-
binant cathelin-like protein. Surprisingly, the results from these
studies displayed antimicrobial activity at concentrations ranging
from16 to 32 mM against bacteria resistant to LL-37. Cathelin-like
protein caused growth inhibition of both Gram-negative (E. coli)
and Gram-positive (S. aureus) bacteria.We also observed that the
parent hCAP18/LL-37 was inactive even at higher concentrations
(464 mM), which is consistent with the previously reported data
on rabbit and bovine cathelicidin precursors puri¢ed from tissue
(Zanetti et al, 1991; Zarember et al, 2002). In rabbit CAP-18, how-
ever, the unprocessed protein has shown synergistic antimicrobial
activity when combined with the antimicrobial and lipopolysac-
charide-binding protein BPI (Zarember et al, 2002). The mech-
anism of this synergistic interaction is unknown. Further studies
are required to determine the spectrum activity of cathelin-like
protein and also to assess the minimal inhibitory activity required
to eliminate these pathogens in vivo. In addition, experiments
combining both cathelin-like proteins and LL-37 peptides are
under way to test for the synergistic e¡ect of these two domains.
How the cathelin-like domain carries out its two distinct
functions, antimicrobial and proteinase inhibition, is at present
unknown. Many cationic and amphipathic peptides such as
indolicidin (Falla et al, 1996) and magainins (Westerho¡ et al,
1989) exert their antimicrobial activity through membrane dis-
ruption and pore forming (Hancock, 1997). Cathelin-like protein
is not a basic protein, however, and therefore the mechanism of
antimicrobial action is probably di¡erent from this class of pep-
tides. One possibility is that cathelin-like protein has structural
features that interact with the microbial membrane. Based on
the proposed three-dimensional structure of the prosequence of
the porcine protegrin-type cathelicidin (Sanchez et al, 2002a), the
N-terminus of this molecule presents an a-helical structure. This
structure could be involved in the disruption of the normal func-
tion of microbial membrane. Furthermore, cystatins are similar
to cathelin-like proteins (reviewed in Zaiou and Gallo, 2002), are
not basic proteins, and also show antibacterial and antiviral activ-
ity against a range of organisms (Takahashi et al, 1994; Blanken-
voorde et al, 1998). A synthetic peptide mimicking the cysteine
proteinase inhibitory site of human cystatin C was found to kill
S. pyogenes (Bjorck et al, 1989). Secretory leukocyte protease inhi-
bitor is a 12 kDa protein that also contains both serine protease
inhibitory and antimicrobial activities (Ashcroft et al, 2000).
Recently, a cysteine proteinase inhibitor, designated L-cystatin,
which is stored in the large granules of horseshoe crab hemocytes,
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was identi¢ed (Agarwala et al, 1996). This molecule is 12,600 kDa,
is similar to cystatin superfamily members, contains two disul¢de
bridges at positions corresponding to the cathelin-like domain,
and has shown antimicrobial activity against Gram-negative bac-
teria. These structural similarities support the function proposed
for the cathelin-like protein. Furthermore, a recent investigation
has solved the crystal structure of a homologous domain from the
porcine cathelicidin protegrin-3 (Sanchez et al, 2002a). These data
con¢rm the similarity between cathelin-like proteins and cysta-
tins, and also demonstrate potential homodimer formation for
this protein as we observed in Fig 1(c).
In summary, the ¢ndings of this study highlight a novel bio-
logic function of cathelin-like protein as an antimicrobial protein
in addition to its proteinase inhibitory activity. Recently, observa-
tions of cathelicidin in human sweat have shown the existence of
cathelicidin processed to the expected size of the cathelin-like do-
main (Murakami et al, 2002). Our data suggest that cathelin-like
protein may play important roles not only in the protection of
cells from unfavorable proteolysis by host and microbial cysteine
proteases, but also in the direct killing or inhibition of invading
pathogens. Several functions for the peptide C-terminal domain
of the cathelicidin gene product have been discovered ranging
from in£uencing proteoglycan expression, angiogenesis, and
chemotaxsis to its antimicrobial e¡ects. This study now shows
that the cathelin-like domain has multiple functions that can have
complementary actions with the mature AMP in tissue defense
(illustrated schematically in Fig 4). A full knowledge of the func-
tion of the di¡erent domains of cathelicidin would be a valuable
asset in understanding normal innate immune defense strategies
in mammals and in attempts to design new antibiotics for use in
treatment or prevention of infectious diseases.
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